DUO-O研究:度伐利尤单抗联合化疗及贝伐珠单抗后续联合或不联合奥拉帕利维持治疗新诊断非BRCA突变晚期卵巢癌
DUO-O是一项III期安慰剂对照试验,纳入新诊断晚期卵巢癌患者,非肿瘤BRCA突变者随机分为三组:对照组(卡铂/紫杉醇+贝伐珠单抗后贝伐珠单抗维持)、度伐利尤单抗组(加用度伐利尤单抗后度伐利尤单抗+贝伐珠单抗维持)、度伐利尤单抗+奥拉帕利组(后加奥拉帕利维持)。主要终点为研究者评估的无进展生存期(PFS)。结果显示,在非tBRCAm HRD阳性人群中,度伐利尤单抗+奥拉帕利组对比对照组PFS HR为0.49(95%CI 0.34-0.69,P<0.0001),中位PFS 37.3 vs 23.0个月;在非tBRCAm ITT人群中HR为0.63(95%CI 0.52-0.76,P<0.0001),中位PFS 24.2 vs 19.3个月。度伐利尤单抗组对比对照组在非tBRCAm ITT人群中PFS HR为0.87(95%CI 0.73-1.04,P=0.13)。最终PFS和中期OS分析显示PFS结果与主要分析一致,度伐利尤单抗+奥拉帕利组对比对照组中期OS HR为0.95(95%CI 0.76-1.20,P=0.68;39.0%成熟度)。安全性 generally 与各药物已知特征一致。
要点
- 非tBRCAm HRD阳性人群中,度伐利尤单抗+奥拉帕利组中位PFS 37.3个月,对照组23.0个月,HR 0.49。
- 非tBRCAm ITT人群中,度伐利尤单抗+奥拉帕利组中位PFS 24.2个月,对照组19.3个月,HR 0.63。
- 度伐利尤单抗组对比对照组在非tBRCAm ITT人群中PFS HR 0.87,P=0.13,未达统计学显著。
核心结论
- DUO-O研究达到主要PFS终点:在非tBRCAm HRD阳性和非tBRCAm ITT人群中,度伐利尤单抗+奥拉帕利维持方案对比对照组显著改善PFS。
研究设计与样本
- DUO-O(NCT03737643)为III期安慰剂对照试验,纳入新诊断晚期卵巢癌患者,非tBRCAm者按1:1:1随机分配至对照组、度伐利尤单抗组或度伐利尤单抗+奥拉帕利组。
主要发现
- 非tBRCAm ITT人群中,度伐利尤单抗+奥拉帕利组对比对照组PFS HR 0.63(95%CI 0.52-0.76,P<0.0001),中位PFS 24.2 vs 19.3个月。
- 非tBRCAm ITT人群中,度伐利尤单抗组对比对照组PFS HR 0.87(95%CI 0.73-1.04,P=0.13),中位PFS 20.6 vs 19.3个月。
- 最终PFS和中期OS分析(数据截止2023年9月18日)显示PFS结果与主要分析一致;非tBRCAm ITT人群中度伐利尤单抗+奥拉帕利组对比对照组中期OS HR 0.95(95%CI 0.76-1.20,P=0.68;39.0%成熟度)。
- 安全性总体与各药物已知特征一致。
关键数值与推荐
- 非tBRCAm HRD阳性人群:度伐利尤单抗+奥拉帕利组对比对照组PFS HR 0.49(95%CI 0.34-0.69,P<0.0001),中位PFS 37.3 vs 23.0个月。
- 非tBRCAm ITT人群:度伐利尤单抗+奥拉帕利组对比对照组PFS HR 0.63(95%CI 0.52-0.76,P<0.0001),中位PFS 24.2 vs 19.3个月。
- 非tBRCAm ITT人群:度伐利尤单抗组对比对照组PFS HR 0.87(95%CI 0.73-1.04,P=0.13),中位PFS 20.6 vs 19.3个月。
- 非tBRCAm ITT人群:度伐利尤单抗+奥拉帕利组对比对照组中期OS HR 0.95(95%CI 0.76-1.20,P=0.68;39.0%成熟度)。
临床怎么用
- 对于新诊断非tBRCAm晚期卵巢癌患者,尤其HRD阳性者,可考虑一线度伐利尤单抗联合卡铂/紫杉醇及贝伐珠单抗后度伐利尤单抗+贝伐珠单抗+奥拉帕利维持治疗。
- 度伐利尤单抗单药联合方案在非tBRCAm ITT人群中PFS未达统计学显著,需结合HRD状态个体化选择。
- 治疗安全性总体与各药物已知特征一致,需关注免疫相关不良反应及奥拉帕利相关毒性。
局限性
- 中期OS分析成熟度仅39.0%,长期生存获益尚待进一步随访。
- 研究未报告其他亚组或生物标志物探索性分析结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite treatment advances in newly diagnosed advanced-stage ovarian cancer (aOC), improved outcomes are needed. PATIENTS AND METHODS: DUO-O (NCT03737643), a phase III placebo-controlled trial, enrolled patients with newly diagnosed aOC. Following one cycle of carboplatin/paclitaxel ± bevacizumab, patients without a tumor BRCA mutation (non-tBRCAm) were randomly assigned (1 : 1 : 1) at cycle 2 to carboplatin/paclitaxel plus bevacizumab followed by bevacizumab (control); carboplatin/paclitaxel, bevacizumab plus durvalumab followed by bevacizumab plus durvalumab (durvalumab arm); or carboplatin/paclitaxel, bevacizumab plus durvalumab followed by bevacizumab, durvalumab plus olaparib (durvalumab + olaparib arm). Investigator-assessed progression-free survival (PFS; primary endpoint) was tested for the durvalumab + olaparib arm versus control in the non-tBRCAm homologous recombination deficiency (HRD)-positive and non-tBRCAm intention-to-treat (ITT) populations. RESULTS: One thousand one hundred and thirty patients were randomly allocated to the study. The prespecified interim PFS analysis [data cut-off (DCO): 5 December 2022] qualified as the primary analysis; PFS hazard ratio (HR) for the durvalumab + olaparib arm versus control was 0.49 [95% confidence interval (CI) 0.34-0.69, P < 0.0001; median (m) PFS 37.3 versus 23.0 months] in the non-tBRCAm HRD-positive and 0.63 (95% CI 0.52-0.76, P < 0.0001; mPFS 24.2 versus 19.3 months) in the non-tBRCAm ITT population. For the durvalumab arm versus control, PFS HR was 0.87 (95% CI 0.73-1.04, P = 0.13; mPFS 20.6 versus 19.3 months) in the non-tBRCAm ITT population. At final PFS and interim overall survival (OS) analysis (DCO: 18 September 2023), PFS results were consistent with primary analysis; interim OS HR for the durvalumab + olaparib arm versus control was 0.95 (95% CI 0.76-1.20, P = 0.68; 39.0% maturity) in the non-tBRCAm ITT population. Safety was generally consistent with the profiles of the individual agents. CONCLUSIONS: DUO-O met its primary PFS endpoints for first-line durvalumab plus carboplatin/paclitaxel and bevacizumab followed by durvalumab, bevacizumab plus olaparib maintenance versus carboplatin/paclitaxel and bevacizumab followed by bevacizumab in the non-tBRCAm HRD-positive and non-tBRCAm ITT populations. Further insight into long-term benefit is anticipated with additional follow-up.
引用
- Harter P, Trillsch F, Okamoto A, et al. Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer. Ann Oncol. 2025. PMID: 41380962. doi:10.1016/j.annonc.2025.11.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。